OKYO Pharma (OKYO Pharma) Growth Rank : 0 (As of Jun. 04, 2024)

View and export this data going back to 2022. Start your Free Trial

What is OKYO Pharma Growth Rank?

OKYO Pharma has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

OKYO Pharma Growth Rank Related Terms

Thank you for viewing the detailed overview of OKYO Pharma's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

OKYO Pharma (OKYO Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OKYO Pharma Ltd (NAS:OKYO) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

OK10:Germany

Address

14/15 Conduit St, Floor 4, London, GBR, W1S 2XJ

Website

https://www.okyopharma.com

OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions on various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.

Executives

John P Brancaccio	director	C/O TAMIR BIOTECHNOLOGY, INC., 11 DEER PARK DRIVE, SUITE 204, MONMOUTH JUNCTION NJ 08852
Gary S Jacob	director, officer: Chief Executive Officer
Gabriele M Cerrone	director, 10 percent owner, officer: Executive Chairman	265 EAST 66TH STREET, SUITE 16G, NEW YORK NY 10021
Bernard Denoyer	director	C/O CALLISTO PHARMACEUTICALS, INC., 420 LEXINGTON AVENUE, SUITE 1609, NEW YORK NY 10170
Willy Jules Simon	director	PLAYLOGIC INTERNATIONAL NV, CONCERTGEBOUWPLEIN 13, AMSTERDAM P7 1071 LL
Keeren Shah	officer: Chief Financial Officer	55 PARK LANE, LONDON X0 W1K 1NA